These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20532182)

  • 1. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
    Mancini G; D'Annessa I; Coletta A; Sanna N; Chillemi G; Desideri A
    PLoS One; 2010 Jun; 5(6):e10934. PubMed ID: 20532182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
    Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
    Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of an Indenoisoquinoline to the topoisomerase-DNA complex induces reduction of linker mobility and strengthening of protein-DNA interaction.
    Mancini G; D'Annessa I; Coletta A; Chillemi G; Pommier Y; Cushman M; Desideri A
    PLoS One; 2012; 7(12):e51354. PubMed ID: 23236483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
    van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
    J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
    Pan P; Li Y; Yu H; Sun H; Hou T
    J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour drugs impede DNA uncoiling by topoisomerase I.
    Koster DA; Palle K; Bot ES; Bjornsti MA; Dekker NH
    Nature; 2007 Jul; 448(7150):213-7. PubMed ID: 17589503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of topoisomerase I poisoning by a camptothecin analog.
    Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
    D'Annessa I; Tesauro C; Wang Z; Arnò B; Zuccaro L; Fiorani P; Desideri A
    Biochim Biophys Acta; 2013 Dec; 1834(12):2712-21. PubMed ID: 24096022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation.
    Wang Z; D'Annessa I; Tesauro C; Croce S; Ottaviani A; Fiorani P; Desideri A
    Biochim Biophys Acta; 2015 Aug; 1854(8):860-8. PubMed ID: 25910424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
    Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
    J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
    Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
    Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunodetection of human topoisomerase I-DNA covalent complexes.
    Patel AG; Flatten KS; Peterson KL; Beito TG; Schneider PA; Perkins AL; Harki DA; Kaufmann SH
    Nucleic Acids Res; 2016 Apr; 44(6):2816-26. PubMed ID: 26917015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
    Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
    Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence.
    Koster DA; Czerwinski F; Halby L; Crut A; Vekhoff P; Palle K; Arimondo PB; Dekker NH
    Nucleic Acids Res; 2008 Apr; 36(7):2301-10. PubMed ID: 18292117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.
    Fiorani P; Bruselles A; Falconi M; Chillemi G; Desideri A; Benedetti P
    J Biol Chem; 2003 Oct; 278(44):43268-75. PubMed ID: 12904303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan.
    Rosa-Teijeiro C; Wagner V; Corbeil A; d'Annessa I; Leprohon P; do Monte-Neto RL; Fernandez-Prada C
    Parasit Vectors; 2021 Aug; 14(1):438. PubMed ID: 34454601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
    Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
    DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.